In-vitro activity of a new oral streptogramin, RPR 106972, alone and in combination with rifampicin or ciprofloxacin against Legionella spp.

被引：4
|
作者：
Pendland, SL
Killian, AD
Woodward, JG
Rodvold, KA
机构：
[1] UNIV ILLINOIS,COLL PHARM,DEPT PHARM PRACTICE MC 886,CHICAGO,IL 60612
[2] UNIV ILLINOIS,COLL MED,CHICAGO,IL 60612
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 1997年 / 39卷 / 05期
关键词：
D O I：
10.1093/jac/39.5.651
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The in-vitro activity of RPR 106972, a new oral streptogramin, was compared with that of erythromycin, ciprofloxacin, and rifampicin against 45 Legionella sop. White rifampicin was the most active of atl agents tested, RPR 106972 demonstrated activity comparable to that of erythromycin and ciprofloxacin. Usually, indifference was seen when RPR 106972 was tested in combination with rifampicin or ciprofloxacin.
引用
收藏
页码：651 / 653
页数：3
相关论文
共 50 条
  • [1] In-vitro activity of gatifloxacin, a novel fluoroquinolone, compared with that of ciprofloxacin against Legionella spp.
    Pendland, SL
    Losnedahl, KJ
    Schriever, CA
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) : 295 - 297
  • [2] In vitro activity of RPR 106972 alone and in combination with vancomycin, ampicillin, and gentamicin against multidrug resistant enterococci
    Messick, CR
    Woodward, J
    Pendland, SL
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 32 (02) : 95 - 99
  • [3] Effect of macrolide resistance on the activity of the oral streptogramin RPR 106972 and its components against Streptococcus pneumoniae
    Jacobs, MR
    Spangler, SK
    Appelbaum, PC
    EXPANDING INDICATIONS FOR THE NEW MACROLIDES, AZALIDES, AND STREPTOGRAMINS, 1997, 21 : 390 - 394
  • [4] The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
    Ridgway, GL
    Salman, H
    Robbins, MJ
    Dencer, C
    Felmingham, D
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 : 31 - 34
  • [5] In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808 RPR106950): A novel orally administered streptogramin combination
    Putnam, SD
    Jones, RN
    Johnson, DM
    Washington, J
    Murray, P
    Knapp, C
    Haugen, T
    Walker, R
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 28 (03) : 139 - 147
  • [6] IN-VITRO ACTIVITY OF ZIDOVUDINE ALONE AND IN COMBINATION WITH CIPROFLOXACIN AGAINST SALMONELLA AND ESCHERICHIA-COLI
    MASCELLINO, MT
    IONA, E
    IEGRI, F
    DEGREGORIS, P
    FARINELLI, S
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1993, 7 (01): : 23 - 28
  • [7] In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp: Enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin
    Martin, SJ
    Pendland, SL
    Chen, C
    Schreckenberger, PC
    Danziger, LH
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 29 (03) : 167 - 171
  • [8] In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.
    Croco, MAT
    Biedenbach, DJ
    Pfaller, MA
    Doern, GV
    Jones, RN
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (05) : 672 - 673
  • [9] Comparative in-vitro activity of levofloxacin against Chlamydia spp.
    Donati, M
    Rumpianesi, F
    Marchetti, F
    Sambri, V
    Cevenini, R
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (05) : 670 - 671
  • [10] In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp.
    Barchiesi, F.
    Giacometti, A.
    Cirioni, O.
    Arzeni, D.
    Kamysz, W.
    Silvestri, C.
    Licci, A.
    Marigliano, A.
    Della Vittoria, A.
    Nadolski, P.
    Lukasiak, J.
    Scalise, G.
    JOURNAL OF CHEMOTHERAPY, 2007, 19 (05) : 514 - 518
12345